Skip to content


  • Poster presentation
  • Open Access

Impact of P2Y12-mediated platelet reactivity on myocardial perfusion of patients with ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention: a cardiac magnetic resonance study

  • 1,
  • 1,
  • 2,
  • 1,
  • 1,
  • 1,
  • 1,
  • 1 and
  • 1
Journal of Cardiovascular Magnetic Resonance201517 (Suppl 1) :P152

  • Published:


  • Clopidogrel
  • Myocardial Perfusion
  • Infarct Size
  • Cardiac Magnetic Resonance
  • P2Y12 Receptor


Whether high platelet reactivity (HPR) at the time of angiography is associated with worse myocardial reperfusion after primary percutaneous coronary intervention (PPCI) for ST-segment elevation myocardial infarction (STEMI) is unknown. This study aimed to assess the impact of HPR on infarct size and reperfusion injury determined by cardiac magnetic resonance (CMR) in patients with STEMI undergoing PPCI.


Patients with STEMI undergoing PPCI and pretreated with a P2Y12-receptor antagonist (clopidogrel, prasugrel or ticagrelor) underwent platelet function testing at the time of angiography and a CMR from 7 to 10 days after the index event. Platelet function testing was performed with the VerifyNow assay. HPR was defined according to expert consensus definitions. Central core laboratory-masked analyses for quantified ventricular function, volumes, infarct size, area at risk (edema), microvascular obstruction, intramyocardial hemorrhage were performed. These latter parameters were compared between HPR and non-HPR patients.


A total of 36 patients were included in the analysis, including 20 (55.5%) with HPR and 16 (44.4%) with non-HPR. No relevant significant differences between HPR and no-HPR groups were found for clinical characteristics, procedural variables, and time intervals. Compared with non-HPR patients, those with HPR had a significantly higher area at risk (p=0.04) and a trend towards higher infact size (p=0.07) (Figure 1). The microvascular obstruction was observed in overall 5 cases (13.9%): 4 (20%) with HPR e in 1 (6.3%) with non-HPR. The intramyocardial hemorrhage was found in 2 patients: one with HPR, but receiving a glycoprotein IIb/IIIa inhibitor in bailout, and one with non-HPR.

Figure 1


In patients with STEMI undergoing PPCI pretreated with a P2Y12 receptor antagonist, the presence of HPR at the time of angiography was associated with higher area at risk and infarct size. These findings suggest the need for achieving at earliest as possible an effective P2Y12-inhibition.



Authors’ Affiliations

Cardiology Division, Ferrarotto Hospital, University of Catania, Catania, Italy
Bristol Heart Institute, University of Bristol, Bristol, UK


© La Manna et al; licensee BioMed Central Ltd. 2015

This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. The Creative Commons Public Domain Dedication waiver ( applies to the data made available in this article, unless otherwise stated.